BullFrog AI (BFRG) Stock Surges 106% After Pharma Drug Discovery Deal

TLDR

• BFRG stock surged more than 106% after announcing a deal with a top five global pharmaceutical company
• The deal uses BullFrog AI’s bfLEAP® platform to find and rank drug targets for major depressive disorder (MDD)
• The one-year agreement includes milestone payments and gives the pharma firm exclusive rights to a selected target candidate for three years
• The MDD treatment market was valued at over $8 billion in 2025 and is projected to top $11 billion by 2032
• CEO Vin Singh called it “strong, high-quality validation” of the company’s AI platform

BullFrog AI Holdings (BFRG) stock is trading at more than double its prior close after Monday’s announcement, with pre-market gains reaching as high as 114% earlier in the session.

Bullfrog AI Holdings, Inc. Common Stock, BFRG

BullFrog AI Holdings signed a one-year feasibility agreement with one of the world’s top five pharmaceutical companies by 2025 revenue. The deal was signed on March 27, 2026, and publicly announced on March 30.

The agreement centres on BullFrog AI’s bfLEAP® platform. The pharma company will use it to identify and rank novel drug targets for major depressive disorder, or MDD.

BullFrog AI said the deal is designed to speed up the partner’s drug discovery and clinical development program for that indication.

Under the terms, the pharmaceutical company can secure exclusive rights to a final selected target candidate for up to three years. The arrangement also includes milestone payments tied to key deliverables, including prioritized targets, causal gene networks, and target dossiers.

The pharma company has not been named. BullFrog AI said full details will be filed in a Form 8-K with the Securities and Exchange Commission.

Singh also said the company expects the relationship to grow into other areas of the partner’s R&D pipeline.

The Platform Behind the Deal

BullFrog AI’s technology stack includes three tools: bfLEAP®, bfPREP, and bfARENAS. Together, they use causal network inference to map complex biological data.

The client can terminate the agreement without cause on 30 days’ notice. Standard breach remedies apply.

The MDD Market

Major depressive disorder is a large and growing therapeutic area. The MDD treatment market was valued at over $8 billion in 2025, according to Stellar Market Research.

It is projected to grow at nearly 5% annually, reaching over $11 billion by 2032.

The warrant ticker BFRGW also moved sharply on the news, rising over 35% on the same day.

BullFrog AI’s current market cap sits at approximately $6.44 million, making the size and profile of its new pharma partner a striking contrast.

The post BullFrog AI (BFRG) Stock Surges 106% After Pharma Drug Discovery Deal appeared first on CoinCentral.